[Skip to Content]
[Skip to Content Landing]
Views 573
Citations 0
Comment & Response
March 12, 2014

Stem Cells and Cardiovascular Drug Development

Author Affiliations
  • 1University of Michigan Medical School, Ann Arbor
  • 2Prince of Wales Hospital, Randwick, New South Wales, Australia

Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA. 2014;311(10):1070. doi:10.1001/jama.2014.631

To the Editor We are hopeful that induced pluripotent stem cells (iPSCs) will lead to powerful drug discovery platforms based on their ability to model disease at the cellular level and will serve as a reservoir of transplantable tissues for many diseases. Dr Mordwinkin and colleagues1 highlighted these aspects to assert that iPSC technology may reduce preclinical drug development times and more accurately predict efficacy and toxicity of novel or off-label therapeutic agents in human cardiomyocytes. However, iPSC-based technology is not the ideal platform for drug and toxicity screening or for the derivation of transplantable tissues.

First Page Preview View Large
First page PDF preview
First page PDF preview